20 completed, 5 terminated, 4 active not recruiting, 1 recruiting. 18 Phase 1, 18 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Completed 13, Terminated 3, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 18 | Completed 15, Terminated 2, Recruiting 1 |
Follow Sangamo Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) ST-503, Sham (No Treatment) - Chronic Neuropathic Pain | Phase 1 / Phase 2 | Recruiting | Sangamo Therapeutics | 27 | 2025-12-04 | 2026-06-01 |
| Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term) Blood sample - Kidney Transplant Rejection, End Stage Renal Disease | Active not recruiting | Sangamo Therapeutics | 11 | 2023-08-15 | 2025-12-04 | |
| Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400. BIVV003, ST-400 - Blood and Lymphatic Diseases | Active not recruiting | Sangamo Therapeutics | 8 | 2021-12-21 | 2025-11-12 | |
| Long-Term Follow-up of Subjects Who Were Treated With ST-920 ST-920 - Fabry Disease, Fabry Disease, Cardiac Variant | Active not recruiting | Sangamo Therapeutics | 32 | 2021-08-16 | 2026-08-20 | |
| Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients TX200-TR101 - Kidney Transplant Rejection, End Stage Renal Disease | Phase 1 / Phase 2 | Completed | Sangamo Therapeutics | 26 | 2021-03-17 | 2026-07-02 |
| Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX SB-318, SB-913, SB-FIX - Hemophilia B, Mucopolysaccharidosis I | Terminated | Sangamo Therapeutics | 13 | 2020-11-03 | 2026-08-13 | |
| Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR) ST-920 - Fabry Disease | Phase 1 / Phase 2 | Completed | Sangamo Therapeutics | 36 | 2019-07-23 | 2026-04-14 |
| A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease Plerixafor, Busulfan, BIVV003 - Sickle Cell Disease | Phase 1 / Phase 2 | Completed | Sangamo Therapeutics | 7 | 2019-03-06 | 2025-09-12 |
| A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) ST-400 Investigational product - Transfusion Dependent Beta-thalassemia | Phase 1 / Phase 2 | Completed | Sangamo Therapeutics | 5 | 2018-03-29 | 2023-12-14 |
| Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I SB-318 - MPS I | Phase 1 / Phase 2 | Terminated | Sangamo Therapeutics | 3 | 2017-05-24 | 2023-01-26 |
| Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II SB-913 - Mucopolysaccharidosis II, MPS II | Phase 1 / Phase 2 | Terminated | Sangamo Therapeutics | 9 | 2017-05-11 | 2022-10-25 |
| Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B SB-FIX - Hemophilia B | Phase 1 | Terminated | Sangamo Therapeutics | 1 | 2016-11-15 | 2024-07-19 |
| Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients SB-728mR-HSPC Infusion 3 days following busulfan conditioning - HIV | Phase 1 | Active not recruiting | City of Hope Medical Center | 12 | 2016-03-10 | 2026-10-02 |
| Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART SB-728mR-T, Cyclophosphamide - Human Immunodeficiency Virus (HIV) | Phase 1 / Phase 2 | Completed | Sangamo Therapeutics | 8 | 2014-08-01 | 2021-03-19 |
| Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T SB-728-T - HIV | Phase 1 / Phase 2 | Completed | Sangamo Therapeutics | 26 | 2011-12-01 | 2021-05-24 |
| Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T There are no disallowed treatments - HIV-1-infection | Terminated | Sangamo Therapeutics | 38 | 2011-03-18 | 2024-01-26 | |
| Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects SB-728-T - HIV, HIV Infection | Phase 1 / Phase 2 | Completed | Sangamo Therapeutics | 21 | 2010-11-01 | 2019-09-20 |
| Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients SB-728-T - HIV Infection, HIV Infections | Phase 1 | Completed | Sangamo Therapeutics | 19 | 2009-12-01 | 2015-03-13 |
| Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy SB-509, Saline - Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | Phase 2 | Completed | Sangamo Therapeutics | 170 | 2009-11-01 | 2022-05-23 |
| Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease CERE-120: Adeno-Associated Virus Delivery of Neurturin, Sham Surgery - Idiopathic Parkinson's Disease | Phase 1 / Phase 2 | Completed | Sangamo Therapeutics | 57 | 2009-10-29 | 2020-04-16 |
Showing 20 of 30. Sign in to see all of them.
Diabetic Neuropathies (5) · Diabetes Mellitus, Type 1 (4) · Diabetes Mellitus, Type 2 (4) · HIV Infections (4) · Parkinson Disease (3) · Acquired Immunodeficiency Syndrome (2) · Alzheimer Disease (2) · Anemia, Sickle Cell (2) · Fabry Disease (2) · Hemophilia B (2) · Kidney Failure, Chronic (2) · Mucopolysaccharidosis I (2) · Mucopolysaccharidosis II (2) · beta-Thalassemia (2) · Amyotrophic Lateral Sclerosis (1)
Busulfan (2) · Cyclophosphamide (2) · Blood Specimen Collection (1) · Saline Solution (1) · Sodium Chloride (1) · Treatment Interruption (1) · plerixafor (1) · salicylhydroxamic acid (1)
United States (28) · United Kingdom (4) · Australia (2) · Belgium (2) · Canada (2) · Germany (2) · Mexico (2) · Netherlands (2) · Italy (1) · Puerto Rico (1) · Taiwan (1)
Joao Siffert, M.D. (2) · Winson Tang, M.D. (2) · Amrita Y. Krishnan, MD (1) · David Stein, MD (1) · Ely Benaim, M.D. (1) · Leo Verhagen Metman, M.D., Ph.D. (1) · Pablo Tebas, MD (1) · Paul S. Aisen, M.D. (1) · William J Marks, Jr., M.D. (1) · Winson Tang, MD (1)
PMID 36299240, PMID 34175041, PMID 18387850, PMID 20970382, PMID 23576625, PMID 24597865, PMID 27900346, PMID 29582053, PMID 32278382, PMID 39800465
2019 (1)